Bartman, Caroline R. http://orcid.org/0000-0002-2147-6003
Weilandt, Daniel R.
Shen, Yihui http://orcid.org/0000-0001-8490-6413
Lee, Won Dong http://orcid.org/0000-0002-2344-171X
Han, Yujiao
TeSlaa, Tara
Jankowski, Connor S. R. http://orcid.org/0000-0003-1247-4548
Samarah, Laith
Park, Noel R.
da Silva-Diz, Victoria
Aleksandrova, Maya
Gultekin, Yetis
Marishta, Argit
Wang, Lin http://orcid.org/0000-0002-9370-6891
Yang, Lifeng
Roichman, Asael http://orcid.org/0000-0001-9538-0103
Bhatt, Vrushank
Lan, Taijin
Hu, Zhixian
Xing, Xi
Lu, Wenyun
Davidson, Shawn http://orcid.org/0000-0002-3475-0382
Wühr, Martin
Vander Heiden, Matthew G. http://orcid.org/0000-0002-6702-4192
Herranz, Daniel http://orcid.org/0000-0003-1768-5969
Guo, Jessie Yanxiang
Kang, Yibin http://orcid.org/0000-0002-1626-6730
Rabinowitz, Joshua D. http://orcid.org/0000-0002-1247-4727
Article History
Received: 3 November 2021
Accepted: 14 December 2022
First Online: 1 February 2023
Competing interests
: J.D.R. is an advisor and stockholder in Colorado Research Partners, L.E.A.F. Pharmaceuticals, Bantam Pharmaceuticals, Barer Institute and Rafael Pharmaceuticals; a paid consultant of Pfizer and Third Rock Ventures; a founder, director and stockholder of Farber Partners, Serien Therapeutics and Sofro Pharmaceuticals; a founder and stockholder in Empress Therapeutics; and a director of the Princeton University–PKU Shenzhen collaboration. M.G.V.H. is a scientific advisor for Agios Pharmaceuticals, iTeos Therapeutics, Sage Therapeutics, Drioa Ventures and Auron Therapeutics. Y.K. is a co-founder and chair of scientific advisory board of Firebrand Therapeutics and KayoThera.